KeyPlants AB Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • KeyPlants AB's estimated annual revenue is currently $19.9M per year.(i)
  • KeyPlants AB's estimated revenue per employee is $201,000

Employee Data

  • KeyPlants AB has 99 Employees.(i)
  • KeyPlants AB grew their employee count by 41% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.1M100-10%N/AN/A
#2
$82.4M41022%N/AN/A
#3
$18.9M94-67%N/AN/A
#4
$19.9M9941%N/AN/A
#5
$42.4M211-36%N/AN/A
#6
$87M43315%N/AN/A
#7
$7.2M3633%N/AN/A
#8
$3M15114%N/AN/A
#9
$18.5M9224%N/AN/A
#10
$4.2M2131%N/AN/A

About us The business of KeyPlants comprises services in connection with challenging projects in any location of the world - project management, design studies & engineering, construction management. We offer to lead the project towards the shortest way to project completion and start-up. Our Value Proposition: Skilled and Experienced employees and partners Committed to deliver results and exceed expectations Predictability through a well established execution model

keywords:N/A

N/A

Total Funding

99

Number of Employees

$19.9M

Revenue (est)

41%

Employee Growth %

N/A

Valuation

N/A

Accelerator

KeyPlants AB News

2019-09-12 - Global Plants LED Grow Light Market Demand,opportunity ...

Heliospectra AB ... To present the key Plants LED Grow Light manufacturers, production, revenue, market share, and recent development.

2017-02-01 - Saudi CDMO's fill/finish plant to offer Big Biopharma access to ...

... firm KeyPlants to design and build a fill/finish plant for biological APIs. ... the former Pharmadule AB main fabrication workshop in Sweden ...

2015-09-18 - Historiskt samarbete i Ryskt miljard läkemedels projekt

KEYPLANTS ERHÅLLER ORDER FÖR HISTORISKT KANADENSISK-RYSKT FARMA PROJEKT. Kanada baserade ProMetic Lifesciences har ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20M99-15%$98.6M
#2
$7.5M100900%N/A
#3
$20.1M100-10%N/A
#4
$27.3M10115%$43M
#5
$31.1M10229%N/A